New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:12 EDTAZN, FRX, IRWDIronwood reports Q4 LINZESS net product sales $51M, as reported by Forest
Ironwood (IRWD) says LINZESS net product sales, as reported by Forest Laboratories (FRX) were $51M in Q4, an increase of approximately 48% quarter over quarter, and $118.8M for the year ended December 31, 2013. More than 220,000 LINZESS prescriptions were filled in Q4, resulting in more than 24% growth in total prescriptions quarter over quarter, and over 580,000 LINZESS prescriptions were filled in 2013, according to IMS Health. In 2013, more than 50,000 healthcare practitioners prescribed LINZESS, including approximately 90% of high prescribing gastroenterologists and approximately 70% of other high prescribing healthcare practitioners, primarily primary care physicians. Physician prescribing continues to increase month over month. Almirall, S.A., Ironwood’s European partner, continues to launch CONSTELLA in Europe. CONSTELLA is currently available to adult IBS-C patients in nine countries in Europe, including the United Kingdom and Germany. Ironwood and AstraZeneca (AZN) continue to enroll patients in a Phase III clinical trial of linaclotide in adult patients with IBS-C in China. The trial is expected to be completed in the first half of 2015. Astellas Pharma Inc. has completed enrollment in a Phase II double-blind, placebo-controlled, dose-ranging clinical trial of linaclotide in adult patients with IBS-C in Japan.
News For IRWD;FRX;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
11:13 EDTAZNBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 23, 2015
09:45 EDTAZNUBS to hold a field trip
Subscribe for More Information
09:06 EDTAZNInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
09:03 EDTAZNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:36 EDTAZNPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
07:55 EDTAZNAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
March 19, 2015
08:37 EDTAZNNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information
March 17, 2015
14:10 EDTAZNIGI Laboratories recent sell-off a buying opportunity, says Craig-Hallum
Subscribe for More Information
March 16, 2015
07:30 EDTAZNAmerican College of Cardiology to hold an expo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use